Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 2
1986 12
1987 7
1988 5
1989 3
1990 3
1991 8
1992 12
1993 2
1994 7
1995 7
1996 10
1997 12
1998 9
1999 10
2000 6
2001 4
2002 5
2003 5
2004 6
2005 5
2006 5
2007 10
2008 4
2009 8
2010 1
2011 2
2012 4
2013 4
2014 2
2015 1
2016 2
2017 2
2018 1
2020 2
2021 4
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.
Sasane R, Bartels A, Field M, Sierra MI, Duvvuri S, Gray DL, Pin SS, Renger JJ, Stone DJ. Sasane R, et al. J Clin Invest. 2021 Jun 1;131(11):e145112. doi: 10.1172/JCI145112. J Clin Invest. 2021. PMID: 33822767 Free PMC article. Clinical Trial.
An epidemiological study of terazosin users showed a lower incidence of Parkinson disease when compared with users of tamsulosin, an alpha1 adrenergic receptor antagonist of a different class that does not activate PGK1. ...Patients were classified as tamsulosin users (n = …
An epidemiological study of terazosin users showed a lower incidence of Parkinson disease when compared with users of tamsulosin, an …
Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial.
Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M. Tehranchi A, et al. Int Braz J Urol. 2013 Nov-Dec;39(6):832-40. doi: 10.1590/S1677-5538.IBJU.2013.06.09. Int Braz J Urol. 2013. PMID: 24456787 Free article. Clinical Trial.
OBJECTIVE: To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort. MATERIALS AND METHODS: Of 163 patients assessed for eligibility, 104 patients were randomly assigned to receive placebo, 2 mg of terazosin twice daily, 2 mg of tolterodine …
OBJECTIVE: To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort. MATERIALS AND METHODS: Of 163 patients …
Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial.
Mokhtari G, Shakiba M, Ghodsi S, Farzan A, Heidari Nejad S, Esmaeili S. Mokhtari G, et al. Urol Int. 2011;87(1):19-22. doi: 10.1159/000323855. Epub 2011 May 18. Urol Int. 2011. PMID: 21597261 Clinical Trial.
OBJECTIVE: We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with internal ureteral stents. ...Nearly all the patients in the placebo group reported flank pain during urination but this was only reported in 5 …
OBJECTIVE: We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with in …
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Pool JL. Pool JL. Am Heart J. 1991 Sep;122(3 Pt 2):926-31. doi: 10.1016/0002-8703(91)90813-w. Am Heart J. 1991. PMID: 1678924 Review.
In a placebo-controlled, double-blind study of terazosin plus atenolol, supine and standing blood pressures decreased significantly from baseline (atenolol monotherapy) after the addition of terazosin but not placebo. ...Preliminary pharmacokinetic results indicate …
In a placebo-controlled, double-blind study of terazosin plus atenolol, supine and standing blood pressures decreased significantly f …
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
Lepor H, Henry D, Laddu AR. Lepor H, et al. Prostate. 1991;18(4):345-55. doi: 10.1002/pros.2990180408. Prostate. 1991. PMID: 1711689 Review.
In the present review, four clinical studies evaluating the efficacy and safety of terazosin, a selective long-acting alpha 1 blocker, for symptomatic BPH are reviewed. ...The cumulative improvement in the mean obstructive, irritative, and total symptom scores was 67%, 35% …
In the present review, four clinical studies evaluating the efficacy and safety of terazosin, a selective long-acting alpha 1 blocker …
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Titmarsh S, Monk JP. Titmarsh S, et al. Drugs. 1987 May;33(5):461-77. doi: 10.2165/00003495-198733050-00003. Drugs. 1987. PMID: 2885169 Review.
Terazosin is a post-synaptic alpha 1-adrenoceptor antagonist with a similar pharmacodynamic profile to prazosin. ...First-dose syncope occurs rarely after terazosin, and can largely be avoided by giving the first dose at bedtime. ...
Terazosin is a post-synaptic alpha 1-adrenoceptor antagonist with a similar pharmacodynamic profile to prazosin. ...First-dose syncop …
Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Witjes WP, et al. Urology. 1997 Feb;49(2):197-205; discussion 205-6. doi: 10.1016/S0090-4295(96)00490-6. Urology. 1997. PMID: 9037281 Free article. Clinical Trial.
OBJECTIVES: To evaluate clinical and urodynamic changes in patients with and without bladder outlet obstruction (BOO) and to compare the clinical and urodynamic results of terazosin treatment between patients with and without BOO. METHODS: In a prospective study, 97 patien …
OBJECTIVES: To evaluate clinical and urodynamic changes in patients with and without bladder outlet obstruction (BOO) and to compare the cli …
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
Saunders E. Saunders E. Am Heart J. 1991 Sep;122(3 Pt 2):936-42. doi: 10.1016/0002-8703(91)90815-y. Am Heart J. 1991. PMID: 1678925 Review.
Changes (mean +/- SE) in sitting diastolic blood pressure from baseline were -8.1 +/- 1.4 mm Hg for terazosin and -5.0 +/- 1.5 mm Hg for propranolol. Terazosin (5 mg) combined with methyclothiazide (2.5 to 5 mg) produced a significantly greater (p less than 0.01) an …
Changes (mean +/- SE) in sitting diastolic blood pressure from baseline were -8.1 +/- 1.4 mm Hg for terazosin and -5.0 +/- 1.5 mm Hg …
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
Lepor H, Laddu A. Lepor H, et al. Br J Urol. 1992 Nov;70 Suppl 1:2-9. doi: 10.1111/j.1464-410x.1992.tb15860.x. Br J Urol. 1992. PMID: 1281728 Review.
The peak urinary flow increased 37% and 12% in the 10 mg and placebo-treated groups, respectively. The adverse events associated with terazosin were relatively minor and reversible. The United States experience has unequivocally demonstrated the short-term safety and effic …
The peak urinary flow increased 37% and 12% in the 10 mg and placebo-treated groups, respectively. The adverse events associated with ter …
Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K. Vashi V, et al. J Clin Pharmacol. 1998 Nov;38(11):1072-6. doi: 10.1177/009127009803801113. J Clin Pharmacol. 1998. PMID: 9824790 Clinical Trial.
Ninety healthy men were assigned to one of six treatment groups: doxazosin; doxazosin plus finasteride; terazosin; terazosin plus finasteride; placebo; and placebo plus finasteride. ...However, Cmax and AUC0-24 of finasteride were significantly higher after coadmini …
Ninety healthy men were assigned to one of six treatment groups: doxazosin; doxazosin plus finasteride; terazosin; terazosin p …
189 results